Volume 387, Issue 10033, Pages 2106-2116 (May 2016) Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial  Prof Jane Elizabeth Norman, MD, Prof Neil Marlow, DM, Claudia-Martina Messow, PhD, Prof Andrew Shennan, MD, Prof Phillip R Bennett, MD, Prof Steven Thornton, DM, Prof Stephen C Robson, MD, Alex McConnachie, PhD, Prof Stavros Petrou, PhD, Prof Neil J Sebire, MD, Prof Tina Lavender, PhD, Sonia Whyte, MSc, Prof John Norrie, MSc  The Lancet  Volume 387, Issue 10033, Pages 2106-2116 (May 2016) DOI: 10.1016/S0140-6736(16)00350-0 Copyright © 2016 Norman et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure Trial profile *Randomised in error, ineligible for treatment, and excluded post-randomisation. †Consent withdrawals for each of the phases refer to consent withdrawal at any time before reaching the outcome for that phase. ‡Losses to follow-up for each of the phases refer to losses to follow-up at any time before reaching the outcome for that phase. §Numbers with missing outcome data refer to each specific outcome only (obstetric, neonatal, and childhood) and are not additive across the stages since women can have outcome data for a later outcome. The Lancet 2016 387, 2106-2116DOI: (10.1016/S0140-6736(16)00350-0) Copyright © 2016 Norman et al. Open Access article distributed under the terms of CC BY Terms and Conditions